Regeneron Pharmaceuticals REGN · NASDAQ
$819.09 +1.67% (+$13.42)
Summary
70 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 28 USD is left as net profit.
- It holds more cash than debt: $2.46B against $1.99B.
- Analysts expect revenue to grow by 22% this fiscal year.
- It bought back its own shares for $3.97B in the last fiscal year, 4.9% of its market value.
What to watch
- Revenue growth is slowing: 5.6% a year over the last 3 years against 11% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 18.6 USD for 1 USD of yearly profit. Over the last five years it was 18.0 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 5.6% a year. For the next fiscal year analysts expect revenue to grow by 22%. Earnings per share grew by 2.8% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 15 USD
- Research and development 42 USD
- Sales and administration 18 USD
- Taxes and other -2.3 USD
- Net profit 28 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 28 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.47%
- Paid out of profit
- 8.8%
You receive $3.70 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 35
- Hold 14
- Sell 0
Today's price within the analysts' price targets
The average target of $856.8 is 4.6% above today's price. 71% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Collaboration Revenue 51%
- Product 44%
- Product and Service, Other 4.9%
By region
- UNITED STATES 90%
- Rest Of World 10%
Collaboration Revenue brings in 51% of revenue.
Segments in detail